• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Lee M. Nadler, MD


  • Barbon CM, Davies JK, Voskertchian A, Kelner RH, Brennan LL, Nadler LM, Guinan EC.Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells.Am J Transplant. 2014 Feb;14(2):305-18.
  • Davies JK, Barbon CM, Voskertchian A, Nadler LM, Guinan EC.Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation.Cell Transplant. 2012;21(9):2047-61.
  • Davies JK, Barbon CM, Voskertchian AR, Nadler LM, Guinan EC.Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade.Journal Of Visualized Experiments : Jo Ve. 2011(49).
  • Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD, For The Cancer Leukemia Group B And Eastern Cooperative Oncology Group .A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.Leuk Lymphoma. 2011 Apr;52(4):587-96.
  • Batista A, Barata JT, Raderschall E, Sallan SE, Carlesso N, Nadler LM, Cardoso AA.Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.Exp Hematol. 2011 Apr;39(4):457-472.e3.
  • Butler MO, Ansén S, Tanaka M, Imataki O, Berezovskaya A, Mooney MM, Metzler G, Milstein MI, Nadler LM, Hirano N.A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.Int Immunol. 2010 Nov;22(11):863-73.
  • Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ.Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.Cancer Res. 2010 May 15;70(10):3915-24.
  • Davies JK, Nadler LM, Guinan EC.Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.Sci Transl Med. 2009 Oct 7;1(1):1ra3.
  • Kondo E,Maecker B,Weihrauch MR,Wickenhauser C,Zeng W,Nadler LM,Schultze JL,von Bergwelt-Baildon MS.Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy.Clin Cancer Res. 2008 Oct 15;14(20):6574-9.
  • Ansen S,Butler MO,Berezovskaya A,Murray AP,Stevenson K,Nadler LM,Hirano N.Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.Clin Cancer Res. 2008 Oct 1;14(19):6125-36.
  • Davies JK,Yuk D,Nadler LM,Guinan EC.Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.Transplantation. 2008 Sep 27;86(6):854-64.
  • Haining WN,Davies J,Kanzler H,Drury L,Brenn T,Evans J,Angelosanto J,Rivoli S,Russell K,George S,Sims P,Neuberg D,Li X,Kutok J,Morgan J,Wen P,Demetri G,Coffman RL,Nadler LM.CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.Clin Cancer Res. 2008 Sep 1;14(17):5626-34.
  • Haining WN,Angelosanto J,Brosnahan K,Ross K,Hahn C,Russell K,Drury L,Norton S,Nadler L,Stegmaier K.High-throughput gene expression profiling of memory differentiation in primary human T cells.BMC Immunol. 2008;9:44.
  • Haining WN, Ebert BL, Subrmanian A, Wherry EJ, Eichbaum Q, Evans JW, Mak R, Rivoli S, Pretz J, Angelosanto J, Smutko JS, Walker BD, Kaech SM, Ahmed R, Nadler LM, Golub TR.Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells.J Immunol. 2008 Aug 1;181(3):1859-68.
  • Davies JK,Gribben JG,Brennan LL,Yuk D,Nadler LM,Guinan EC.Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.Blood. 2008 Sep 15;112(6):2232-41.
  • Nadler LM, Roberts WC.Lee Marshall Nadler, MD: a conversation with the editor.Proc (Bayl Univ Med Cent). 2007 Oct;20(4):381-9.
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS.Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.Biol Blood Marrow Transplant. 2007 Sep;13(9):1057-65.
  • Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS.Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up.J Clin Oncol. 2007 Jun 20;25(18):2554-9.
  • Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell.Clin Cancer Res. 2007 Mar 15;13(6):1857-1867.
  • Hirano N, Butler M, Xia Z, Berezovskaya A, Murray AP, Ansen S, Kojima S, Nadler LM.Identification of an immunogenic CD8+ T cell epitope derived from {gamma}-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.Blood. 2006 Oct 15;108(8):2662-8.
  • Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Nadler LM.Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.Clin Cancer Res. 2006 May 15;12(10):2967-75.
  • Veiga JP, Costa LF, Sallan SE, Nadler LM, Cardoso AA.Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival.Exp Hematol. 2006 May;34(5):610-21.
  • Zander T, Yunes JA, Cardoso AA, Nadler LM.Rapid, reliable and inexpensive quality assessment of biotinylated cRNA.Braz J Med Biol Res. 2006 May;39(5):589-93.
  • von Bergwelt-Baildon M, Shimabukuro-Vornhagen A, Popov A, Klein-Gonzalez N, Fiore F, Debey S, Draube A, Maecker B, Menezes I, Nadler LM, Schultze JL.CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants.Blood. 2006 Apr 1;107(7):2786-9.
  • Maia S, Haining WN, Ansén S, Xia Z, Armstrong SA, Seth NP, Ghia P, den Boer ML, Pieters R, Sallan SE, Nadler LM, Cardoso AA.Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.Cancer Res. 2005 Nov 1;65(21):10050-8.
  • Hirano N, Butler MO, Xia Z, Ansén S, von Bergwelt-Baildon MS, Neuberg D, Freeman GJ, Nadler LM.Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.Blood. 2006 Feb 15;107(4):1528-36.
  • Costa LF, Balcells M, Edelman ER, Nadler LM, Cardoso AA.Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.Blood. 2006 Jan 1;107(1):285-92.
  • Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM.Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.Blood. 2005 Dec 15;106(13):4389-96.
  • Weihrauch MR, Ansén S, Jurkiewicz E, Geisen C, Xia Z, Anderson KS, Gracien E, Schmidt M, Wittig B, Diehl V, Wolf J, Bohlen H, Nadler LM.Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.Clin Cancer Res. 2005 Aug 15;11(16):5993-6001.
  • Maecker B, von Bergwelt-Baildon MS, Anderson KS, Vonderheide RH, Anderson KC, Nadler LM, Schultze JL.Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients.Clin Exp Immunol. 2005 Sep;141(3):558-62.
  • Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM.Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.Clin Cancer Res. 2005 Jun 15;11(12):4430-6.
  • Haining WN, Neuberg DS, Keczkemethy HL, Evans JW, Rivoli S, Gelman R, Rosenblatt HM, Shearer WT, Guenaga J, Douek DC, Silverman LB, Sallan SE, Guinan EC, Nadler LM.Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.Blood. 2005 Sep 1;106(5):1749-54.
  • Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS.Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 2005 Apr 1;23(10):2208-14.
  • Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC.Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.Exp Hematol. 2005 Mar;33(3):286-94.
  • Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL.Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.Int J Cancer. 2005 Jun 10;115(2):333-6.
  • Hirano N, Butler MO, Guinan EC, Nadler LM, Kojima S.Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients.Br J Haematol. 2005 Jan;128(2):221-3.
  • Barata JT, Keenan TD, Silva A, Nadler LM, Boussiotis VA, Cardoso AA.Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia.Haematol Hematol J. 2004 Dec;89(12):1459-67.
  • Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS.Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.Blood. 2005 Jan 15;105(2):489-95.
  • Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA.Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.J Exp Med. 2004 Sep 6;200(5):659-69.
  • Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS.Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.Leuk Lymphoma. 2004 Feb;45(2):315-20.
  • Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM.Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.Clin Cancer Res. 2004 Feb 1;10(3):828-39.
  • Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP, Sallan SE, Look AT, Nadler LM, Cardoso AA.IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.Blood. 2004 Mar 1;103(5):1891-900.
  • Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O'Connor KC, Schur PH, Kojima S, Guinan EC, Nadler LM.Autoantibodies frequently detected in patients with aplastic anemia.Blood. 2003 Dec 15;102(13):4567-75.
  • Tzachanis D, Appleman LJ, Van Puijenbroek AA, Berezovskaya A, Nadler LM, Boussiotis VA.Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification.J Immunol. 2003 Aug 15;171(4):1691-6.
  • Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, Schultze JL.The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells.Blood. 2003 Nov 1;102(9):3287-94.
  • Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL.Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.Br J Haematol. 2003 Jun;121(6):842-8.
  • Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G.MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.Cancer Immun. 2003 Mar 17;3:3.
  • Nadler LM, Schultze JL.From genomics to cancer vaccines: patient-tailored or universal vaccines?.Curr Opin Mol Ther. 2002 Dec;4(6):572-6.
  • Grader-Beck T, van Puijenbroek AA, Nadler LM, Boussiotis VA.cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression.Blood. 2003 Feb 1;101(3):998-1006.
  • Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K.HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.J Immunol. 2002 Jun 1;168(11):5900-6.
  • von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL.Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.Blood. 2002 May 1;99(9):3319-25.
  • Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, Boussiotis VA.CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.J Immunol. 2002 Mar 15;168(6):2729-36.
  • Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA.Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses.Blood. 2002 Feb 15;99(4):1465-73.
  • Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, Hahn WC, Nadler LM.Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.Cancer Res. 2001 Dec 1;61(23):8366-70.
  • Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM.Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.Clin Cancer Res. 2001 Nov;7(11):3343-8.
  • Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA.Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells.Nat Immunol. 2001 Dec;2(12):1174-82.
  • Friedberg JW, Neuberg D, Monson E, Jallow H, Nadler LM, Freedman AS.The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma.Biol Blood Marrow Transplant. 2001;7(8):446-53.
  • Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL, Nadler LM.CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity.Int J Oncol. 2001 Oct;19(4):791-8.
  • Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM.A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.Br J Haematol. 2001 May;113(2):455-60.
  • Robinson SN, Freedman AS, Neuberg DS, Nadler LM, Mauch PM.Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.Exp Hematol. 2000 Dec;28(12):1325-33.
  • Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM.Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms.Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):210-5.
  • Stripecke R, Cardoso AA, Pepper KA, Skelton DC, Yu XJ, Mascarenhas L, Weinberg KI, Nadler LM, Kohn DB.Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses.Blood. 2000 Aug 15;96(4):1317-26.
  • Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.Cancer J. 2000 May-Jun;6(3):146-50.
  • Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, Nadler LM.p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes.Nat Med. 2000 Mar;6(3):290-7.
  • Cardoso AA, Veiga JP, Ghia P, Afonso HM, Haining WN, Sallan SE, Nadler LM.Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies.Blood. 1999 Nov 15;94(10):3531-40.
  • Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS.Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 1999 Oct;17(10):3128-35.
  • Vonderheide RH, Hahn WC, Schultze JL, Nadler LM.The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.Immunity. 1999 Jun;10(6):673-9.
  • Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG.Transplantation of anergic histoincompatible bone marrow allografts.N Engl J Med. 1999 Jun 3;340(22):1704-14.
  • Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, Clark EA, Nadler LM.The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor.J Immunol. 1998 Sep 15;161(6):2708-15.
  • Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM.CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.J Clin Invest. 1997 Dec 1;100(11):2757-65.
  • Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM.Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival.Blood. 1998 Jan 1;91(1):244-51.
  • Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, Pinkus GS, Nadler LM.In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation.Blood. 1997 Dec 1;90(11):4297-306.
  • Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG.Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease.Blood. 1997 Nov 15;90(10):4212-21.
  • Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM.Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1.Science. 1997 Oct 3;278(5335):124-8.
  • Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM.Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro.Blood. 1997 May 15;89(10):3806-16.
  • Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J.CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.Blood. 1997 Apr 15;89(8):3039-47.
  • Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM.Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation.J Exp Med. 1996 Aug 1;184(2):365-76.
  • Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE, Gribben JG, Nadler LM.Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen.Blood. 1996 Jul 1;88(1):41-8.
  • Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM.Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool.Blood. 1996 Jun 1;87(11):4887-93.
  • Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD.B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.J Immunol. 1996 Feb 1;156(3):1126-31.
  • Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM.Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8200-4.
  • Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD.Role of B7-1 in mediating an immune response to myeloid leukemia cells.Blood. 1995 May 1;85(9):2507-15.
  • Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM.CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy.J Exp Med. 1994 Nov 1;180(5):1665-73.
  • Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM.In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease.Blood. 1994 Feb 1;83(3):793-8.
  • Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM.Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11059-63.
  • Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM.Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.Science. 1993 Nov 5;262(5135):909-11.
  • Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM.B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance.J Exp Med. 1993 Nov 1;178(5):1753-63.
  • Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM.Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6586-90.
  • Galvin F, Freeman GJ, Razi-Wolf Z, Hall W, Benacerraf B, Nadler L, Reiser H.Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation.J Immunol. 1992 Dec 15;149(12):3802-8.
  • Freedman AS, Freeman GJ, Rhynhart K, Nadler LM.Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway.Cell Immunol. 1991 Oct 15;137(2):429-37.
  • Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou LJ, White M, Fingeroth JD, Gribben JG, Nadler LM.Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7.J Exp Med. 1991 Sep 1;174(3):625-31.
  • Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM.B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6575-9.
  • Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM.B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells.J Immunol. 1989 Oct 15;143(8):2714-22.
  • Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM.B7, a B-cell-restricted antigen that identifies preactivated B cells.J Immunol. 1987 Nov 15;139(10):3260-7.